SAT-462 First-in-human single and multiple ascending dose study of AZD2389, a potent inhibitor of fibroblast activation protein, in healthy participants to evaluate safety, tolerability, pharmacokinetics and target engagement
Year: 2025
Type: conference-abstract
Source: Journal of Hepatology
Authors: Vian Azzu, Samuel Daniels, Mathias Liljeblad, Tiffany Schärer, Mohammad Niazi, Amparo Casanova, David Janzén, Deepa Arya, Victoria Parker, Karin Björhall, Anna Bogstedt, Tasso Miliotis, Pavlo Garkaviy, Jelena Saillard, Mahssa Karimi, Armando Flor
Language: English
Subfield: Biochemistry
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4410172895
